Applications for innovative proposals to harness canSERV's unified oncology services are now being invited. A first of its kind, the largest European-wide consortium of research infrastructures is offering free-of-charge transnational access to cutting-edge services to develop breakthrough personalised cancer treatments.
The complexity of cancer requires a multidisciplinary treatment approach, integrating patient- and tumour-specific information at different levels. As part of Europe’s Cancer Mission and Beating Cancer Plan, the EU-funded canSERV project bundles the expertise from 13 European leading life science research infrastructures, ranging from cancer discovery to clinical practice. These services are made available through funded Transnational Access (TNA) calls, providing cancer researchers across Europe access to more than 400 customised world-class oncology services and state-of-the-art technologies, fostering personalised treatments for patients.
Prof. Jens K. Habermann, Director General of BBMRI-ERIC, that is coordinating canSERV, said: "These grants offer a unique chance for cross-domain, interdisciplinary, research proposals to accelerate personalised oncology practice.”
For the very first call, canSERV has joined forces with the EU-funded projects EOSC4Cancer and UNCAN to accelerate knowledge in personalised oncology with focus on multi-level data-based treatment guidance linked to Molecular Tumour Boards.
Specifically, canSERV welcomes excellent research applications on the following challenges:
1. Data-driven treatment selection for localised tumours with multiple patient-derived data types to support novel treatment and diagnostics.
2. Precision treatment guidance for metastatic cancer, especially colorectal cancer, based on multiple sources.
Cancer researchers from research institutes and SMEs all over the world may apply for a combination of free-of-charge research services including: i) Disease Models, ii) Advanced Technologies for Personalised Oncology, iii) Biomarker research, development, and validation, iv) New Therapeutic solutions, v) Accelerated Translation into Personalised Oncology Clinical Practice, vi) Open Digital Research Services and vii) Access to human samples and data. Ideally, these services range across domains to facilitate a multi-modal data approach.
Applications will be reviewed by an international, independent, expert review panel. For more information, visit: www.canSERV.eu
